Smallpox vaccine - CJ Corporation

Drug Profile

Smallpox vaccine - CJ Corporation

Alternative Names: CJ-50300

Latest Information Update: 29 Apr 2015

Price : $50

At a glance

  • Originator CJ Corporation; CJ HealthCare
  • Developer CJ Corporation
  • Class Antivirals; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Smallpox

Most Recent Events

  • 31 Dec 2011 CJ Corporation completes a phase III trial in Smallpox (prevention) in South Korea (NCT01317238)
  • 02 Aug 2011 CJ Corporation completes enrolment in its phase III trial for Smallpox (prevention) in South Korea (NCT01317238)
  • 31 Mar 2011 CJ Corporation intiates enrolment in a phase III trial in previously vaccinated healthy volunteers in South Korea (NCT01317238)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top